Intensive monitoring for post-transplant diabetes mellitus and treatment with dipeptidyl peptidase-4 inhibitor therapy

Srivathsan Thiruvengadam, Brian Hutchison, Wai Lim, Kirsten Bennett, Gloria Daniels, Narelle Cusack, Angela Jacques, Brett Cawley, Shreyas Thiruvengadam, Aron Chakera

Research output: Contribution to journalArticle

Abstract

Aim: Current monitoring practices fail to diagnose patients with post-transplant hyperglycaemia and tend to delay initiation of treatment, which potentially results in adverse graft and morbidity outcomes. This real-world study set out to assess the impact on insulin resistance indices of a new clinical pathway for diagnosis and treatment of hyperglycaemia following renal transplantation. Methods: A hundred and forty-seven adult renal transplant recipients, without pre-existing diabetes, from a single centre were included. Patients transplanted between January 2008 to September 2015 formed the historical cohort. Patients transplanted between October 2015 and February 2018 were subject to a new clinical pathway - if they had fasting blood sugar levels more than 7 mmol/L or random blood glucose levels more than 11.1 mmol/L, they had early introduction of oral therapy, using the DPP-4 inhibitor linagliptin. Results: In the historical cohort, 19.8% were diagnosed with PTDM, compared to 46.3% in the protocol cohort. Amongst patients with PTDM, there was a significant difference in HOMA-IR (p = 0.02) between the historical cohort (median HOMA-IR 3.33) and the protocol cohort (median HOMA-IR 2.21). There was a significant difference at each time point (0,1,2-h measurements) of blood glucose levels form oral glucose tolerance testing between patients with and without PTDM in the historical cohort (p < 0.001), but no difference between patients in the protocol cohort. Conclusion: Detection of PTDM was higher with the new clinical pathway. Early treatment of hyperglycaemia resulted in better insulin resistance scores. Larger prospective controlled studies focussing on early detection and management of PTDM with linagliptin are warranted.

Original languageEnglish
Pages (from-to)1857-1863
Number of pages7
JournalDiabetes and Metabolic Syndrome: Clinical Research and Reviews
Volume13
Issue number3
DOIs
Publication statusPublished - 1 May 2019
Externally publishedYes

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Diabetes Mellitus
Transplants
Critical Pathways
Hyperglycemia
Blood Glucose
Insulin Resistance
Therapeutics
Glucose Tolerance Test
Kidney Transplantation
Fasting
Prospective Studies
Morbidity
Kidney

Cite this

Thiruvengadam, Srivathsan ; Hutchison, Brian ; Lim, Wai ; Bennett, Kirsten ; Daniels, Gloria ; Cusack, Narelle ; Jacques, Angela ; Cawley, Brett ; Thiruvengadam, Shreyas ; Chakera, Aron. / Intensive monitoring for post-transplant diabetes mellitus and treatment with dipeptidyl peptidase-4 inhibitor therapy. In: Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2019 ; Vol. 13, No. 3. pp. 1857-1863.
@article{da60d94e2d5d4aed963e1fddf84f0845,
title = "Intensive monitoring for post-transplant diabetes mellitus and treatment with dipeptidyl peptidase-4 inhibitor therapy",
abstract = "Aim: Current monitoring practices fail to diagnose patients with post-transplant hyperglycaemia and tend to delay initiation of treatment, which potentially results in adverse graft and morbidity outcomes. This real-world study set out to assess the impact on insulin resistance indices of a new clinical pathway for diagnosis and treatment of hyperglycaemia following renal transplantation. Methods: A hundred and forty-seven adult renal transplant recipients, without pre-existing diabetes, from a single centre were included. Patients transplanted between January 2008 to September 2015 formed the historical cohort. Patients transplanted between October 2015 and February 2018 were subject to a new clinical pathway - if they had fasting blood sugar levels more than 7 mmol/L or random blood glucose levels more than 11.1 mmol/L, they had early introduction of oral therapy, using the DPP-4 inhibitor linagliptin. Results: In the historical cohort, 19.8{\%} were diagnosed with PTDM, compared to 46.3{\%} in the protocol cohort. Amongst patients with PTDM, there was a significant difference in HOMA-IR (p = 0.02) between the historical cohort (median HOMA-IR 3.33) and the protocol cohort (median HOMA-IR 2.21). There was a significant difference at each time point (0,1,2-h measurements) of blood glucose levels form oral glucose tolerance testing between patients with and without PTDM in the historical cohort (p < 0.001), but no difference between patients in the protocol cohort. Conclusion: Detection of PTDM was higher with the new clinical pathway. Early treatment of hyperglycaemia resulted in better insulin resistance scores. Larger prospective controlled studies focussing on early detection and management of PTDM with linagliptin are warranted.",
keywords = "Diabetes mellitus/drug therapy, Hypoglycaemic agents/therapeutic use, Renal transplantation/adverse effects",
author = "Srivathsan Thiruvengadam and Brian Hutchison and Wai Lim and Kirsten Bennett and Gloria Daniels and Narelle Cusack and Angela Jacques and Brett Cawley and Shreyas Thiruvengadam and Aron Chakera",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.dsx.2019.04.020",
language = "English",
volume = "13",
pages = "1857--1863",
journal = "Diabetes and Metabolic Syndrome: Clinical Research and Reviews",
issn = "1871-4021",
publisher = "Elsevier",
number = "3",

}

Intensive monitoring for post-transplant diabetes mellitus and treatment with dipeptidyl peptidase-4 inhibitor therapy. / Thiruvengadam, Srivathsan; Hutchison, Brian; Lim, Wai; Bennett, Kirsten; Daniels, Gloria; Cusack, Narelle; Jacques, Angela; Cawley, Brett; Thiruvengadam, Shreyas; Chakera, Aron.

In: Diabetes and Metabolic Syndrome: Clinical Research and Reviews, Vol. 13, No. 3, 01.05.2019, p. 1857-1863.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intensive monitoring for post-transplant diabetes mellitus and treatment with dipeptidyl peptidase-4 inhibitor therapy

AU - Thiruvengadam, Srivathsan

AU - Hutchison, Brian

AU - Lim, Wai

AU - Bennett, Kirsten

AU - Daniels, Gloria

AU - Cusack, Narelle

AU - Jacques, Angela

AU - Cawley, Brett

AU - Thiruvengadam, Shreyas

AU - Chakera, Aron

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Aim: Current monitoring practices fail to diagnose patients with post-transplant hyperglycaemia and tend to delay initiation of treatment, which potentially results in adverse graft and morbidity outcomes. This real-world study set out to assess the impact on insulin resistance indices of a new clinical pathway for diagnosis and treatment of hyperglycaemia following renal transplantation. Methods: A hundred and forty-seven adult renal transplant recipients, without pre-existing diabetes, from a single centre were included. Patients transplanted between January 2008 to September 2015 formed the historical cohort. Patients transplanted between October 2015 and February 2018 were subject to a new clinical pathway - if they had fasting blood sugar levels more than 7 mmol/L or random blood glucose levels more than 11.1 mmol/L, they had early introduction of oral therapy, using the DPP-4 inhibitor linagliptin. Results: In the historical cohort, 19.8% were diagnosed with PTDM, compared to 46.3% in the protocol cohort. Amongst patients with PTDM, there was a significant difference in HOMA-IR (p = 0.02) between the historical cohort (median HOMA-IR 3.33) and the protocol cohort (median HOMA-IR 2.21). There was a significant difference at each time point (0,1,2-h measurements) of blood glucose levels form oral glucose tolerance testing between patients with and without PTDM in the historical cohort (p < 0.001), but no difference between patients in the protocol cohort. Conclusion: Detection of PTDM was higher with the new clinical pathway. Early treatment of hyperglycaemia resulted in better insulin resistance scores. Larger prospective controlled studies focussing on early detection and management of PTDM with linagliptin are warranted.

AB - Aim: Current monitoring practices fail to diagnose patients with post-transplant hyperglycaemia and tend to delay initiation of treatment, which potentially results in adverse graft and morbidity outcomes. This real-world study set out to assess the impact on insulin resistance indices of a new clinical pathway for diagnosis and treatment of hyperglycaemia following renal transplantation. Methods: A hundred and forty-seven adult renal transplant recipients, without pre-existing diabetes, from a single centre were included. Patients transplanted between January 2008 to September 2015 formed the historical cohort. Patients transplanted between October 2015 and February 2018 were subject to a new clinical pathway - if they had fasting blood sugar levels more than 7 mmol/L or random blood glucose levels more than 11.1 mmol/L, they had early introduction of oral therapy, using the DPP-4 inhibitor linagliptin. Results: In the historical cohort, 19.8% were diagnosed with PTDM, compared to 46.3% in the protocol cohort. Amongst patients with PTDM, there was a significant difference in HOMA-IR (p = 0.02) between the historical cohort (median HOMA-IR 3.33) and the protocol cohort (median HOMA-IR 2.21). There was a significant difference at each time point (0,1,2-h measurements) of blood glucose levels form oral glucose tolerance testing between patients with and without PTDM in the historical cohort (p < 0.001), but no difference between patients in the protocol cohort. Conclusion: Detection of PTDM was higher with the new clinical pathway. Early treatment of hyperglycaemia resulted in better insulin resistance scores. Larger prospective controlled studies focussing on early detection and management of PTDM with linagliptin are warranted.

KW - Diabetes mellitus/drug therapy

KW - Hypoglycaemic agents/therapeutic use

KW - Renal transplantation/adverse effects

UR - http://www.scopus.com/inward/record.url?scp=85064545189&partnerID=8YFLogxK

U2 - 10.1016/j.dsx.2019.04.020

DO - 10.1016/j.dsx.2019.04.020

M3 - Article

VL - 13

SP - 1857

EP - 1863

JO - Diabetes and Metabolic Syndrome: Clinical Research and Reviews

JF - Diabetes and Metabolic Syndrome: Clinical Research and Reviews

SN - 1871-4021

IS - 3

ER -